New data on Yasmin VTE risk

New evidence suggests that the combined oral contraceptive Yasmin (drospirenone + ethinylestradiol) may be associated with a slightly higher risk of venous thromboembolism (VTE) than previously thought. Although firm conclusions cannot yet be drawn, the likelihood of this rare adverse event in women taking Yasmin is now thought to lie somewhere between that for levonorgestrel-containing pills and that for desogestrel or gestodene-containing pills.

When used appropriately, the benefits of combined oral contraceptives far outweigh the risk of VTE. However, prescribers should consider the new findings during contraceptive consultations and should exercise caution when prescribing Yasmin or any other combined oral contraceptive to women with risk factors for VTE (eg BMI >30kg/m2).

View Yasmin drug record

Further information: MHRA Drug Safety Update

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more